Influenza Vaccine Vasculitis — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Safe and strongly recommended; inactivated vaccine safe on all DMARDs/biologics; response may be blunted but partial protection valuable
The best answer is “Safe and strongly recommended; inactivated vaccine safe on all DMARDs/biologics; response may be blunted but partial protection valuable”. Safe and strongly recommended; inactivated vaccine safe on all DMARDs/biologics; response may be blunted but partial protection valuable is supported by the cited UK or directly applicable specialist authority and best matches the tested threshold, complication or monitoring principle. The remaining choices—“Worsens vasculitis, with clinical reassessment, with clinical reassessment, within a rheumatology pathway, after safety review, after specialist assessment, because this is a supported alternative”, “unsuitable, within a rheumatology pathway, within a rheumatology pathway, after safety review, after specialist assessment, with clinical reassessment, after specialist review”, “principally live available, after safety review, after safety review, after specialist assessment, with clinical reassessment, within a rheumatology pathway”, “Wait until off treatment, after specialist assessment, with clinical reassessment, within a rheumatology pathway, after safety review”—are credible in related rheumatology presentations, but each addresses a different diagnosis, investigation, treatment sequence or complication and does not fit the decisive findings in this stem.
Reference: EULAR vaccination recommendations for autoimmune inflammatory rheumatic disease: https://pmc.ncbi.nlm.nih.gov/articles/PMC6943061/